Eledon Pharmaceuticals
ELDN· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock -63.3% in FY2025
David-Alexandre C. Gros, M.D. is the CEO of Eledon Pharmaceuticals and was paid $3.2M in FY2025 (Dec), down 43%.
Pay$100 in the stock at the end of FY21 → $34
Executives3
See all- 1David-Alexandre C. Gros, M.D.Chief Executive OfficerFY2025
- 2Steven Perrin, Ph.D.President and Chief Scientific OfficerFY2025
- 3Paul LittleChief Financial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allEledon Pharmaceuticals paid its 3 named executives $6.5M in total in FY2025 (Dec). CEO David-Alexandre C. Gros, M.D. was paid $3.2M of that.
| Name | |||
|---|---|---|---|
| David-Alexandre C. Gros, M.D.Chief Executive Officer | |||
| Steven Perrin, Ph.D.President and Chief Scientific Officer | |||
| Paul LittleChief Financial Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Eledon Pharmaceuticals. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board4
See all- John S. McBrideDirector · 8 yr on the boardIndependentAudit (Chair), Compensation—Paid as an executive
- Steven Perrin, Ph.D.Director · 5 yr on the boardNot independent—Paid as an executive
- Jan Hillson, M.D.Director · 4 yr on the boardIndependentNominating and Corporate Governance, Science and Technology—Paid as an executive
- James RobinsonDirector · 2 yr on the boardIndependentAudit, Compensation (Chair)—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 30, 2026 | FY2025 |
| Annual report | 10-K | Mar 19, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 29, 2025 | FY2024 |
| Annual report | 10-K | Mar 20, 2025 | FY2024 |
| Proxy statement | DEF 14A | May 30, 2024 | FY2023 |
| Annual report | 10-K | Mar 28, 2024 | FY2023 |
